Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are potent weight-management agents; however, their efficacy and safety profiles in patients with obesity and IBD specifically regarding gastrointestinal tolerability remain poorly characterized.<h4>Methods</h4>We conducted a systematic review to evaluate the impact of GLP-1 RAs on anthropometric outcomes in patients with obesity and IBD. Here, GLP1R is linked to inflammatory bowel disease.